Trial Search Results

A Randomized Control Trial Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Blood Sugars.

The purpose of this study is to determine if the use of Linjeta(tm) insulin when compared to Humalog will result in significantly lower episodes of hyperglycemia and hypoglycemia after a breakfast meal.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Biodel

Stanford Investigator(s):


  • Drug: LINjeta U-100 Insulin
  • Drug: Humalog U-100


Phase 2


Inclusion Criteria:1)Type 1 diabetes for at least 1 year

   1. The diagnosis of type 1 diabetes is based on the investigator¡-s judgment; C peptide
   level and antibody determinations are not needed.

   2) Age : 18 years old ¨C 49.99 years old 3) Continuous subcutaneous insulin infusion
   (CSII) therapy for at least 3 months 4) Participant consent demonstrated by signing
   IRB approved documents 6) HgA1c ¡Ü 9% 7) If participant is female with reproductive
   potential, willing to avoid pregnancy and pregnancy test negative. Exclusion
   Criteria:1) Chronic oral steroid use

   2) The presence of a significant medical disorder that in the judgment of the
   investigator will affect the wearing of sensors or the completion of any aspect of the

   3) Known clinical history of celiac disease or inflammatory bowel disease. 4)
   Participants will have a negative anti-endomysial antibody or anti-tissue
   transglutaminase antibody within one year of enrollment.

   5) Cystic Fibrosis 6) Inpatient psychiatric treatment in the past 6 months. 7)
   Currently pregnant or lactating, or anticipate getting pregnant in the next one year.

   8) Clinical diagnosis of gastroparesis. 9) Insulin binding capacity greater than 10
   microunits per litter

Ages Eligible for Study

18 Years - 50 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Parul Patel